Immune Response and Pharmacy - Clinical Research Informer

Arexvy Shows Strong Efficacy Over Three RSV Seasons in New Phase III Data

XTalks

OCTOBER 11, 2024

The vaccine uses recombinant RSV glycoprotein F, stabilized in its prefusion conformation (RSVPreF3), along with GSK’s AS01E adjuvant to boost the immune response — the same adjuvant used in Shingrix, its shingles vaccine, but at a lower dose. This has reportedly led to a two-thirds drop in vaccine demand this season.

Vaccination

Vaccination Vaccine Immune Response Trials

FluMist Takes Flu Protection Home: FDA Approves Self-Administration

XTalks

SEPTEMBER 25, 2024

However, it still requires a prescription, and those choosing the self-administration option will complete a screening process through an online pharmacy before receiving the vaccine. The introduction of FluMist Home, an online pharmacy service, is expected to streamline access even further.

FDA Approval

FDA Approval Vaccination Vaccine Pharmacy

Shape Therapeutics-Roche’s Deal; AllStripes Raises $50M; Datavant-Real Chemistry’s Partnership; BlueWillow’s Nasal Vaccine

Delveinsight

AUGUST 26, 2021

Through the collaboration, the companies focus on connecting clinical trial data with specialty pharmacy information, natural history, registry data, and broad claims databases. Researchers will compare the two-time points to recognize the optimum timing of peak immune response following nasal vaccination.

Vaccination

Vaccination Vaccine Gene Therapy RNA

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

20/20 Offering Lab Test for Measuring Antibody Levels Associated with Vaccine Efficacy

The Pharma Data

DECEMBER 16, 2020

The presence of serum antibodies against an infectious agent may be an indicator of immunity against said agent. These fingerstick collection kits will be especially useful at pharmacies administering vaccines that do not employ phlebotomists. 20/20’s Chief Scientific Officer.

Antibody

Antibody Vaccination Vaccine Immune Response

COVID-19 nasal vaccine candidate effective at preventing disease transmission

The Pharma Data

SEPTEMBER 30, 2021

. “However, mucosal vaccination has been hampered by the shortage of efficient delivery of the antigen and therefore the need for appropriate adjuvants which will stimulate a strong immune reaction without toxicity.” A fundamental limitation of intramuscular vaccines is that they’re not designed to elicit mucosal immunity.

Vaccination

Vaccination Vaccine Immune Response Licensing

How the UAE’s COVID-19 Vaccination Strategy Differs from North America’s and Why It Matters

XTalks

FEBRUARY 3, 2021

However, the World Health Organization ( WHO ) stated that they are still learning about immunity to COVID-19. Therefore, the WHO believes that until we better understand COVID-19 immunity, it will not be possible to know how much of the population is immune, and how long that immunity will last, to make future predictions.

Vaccination

Vaccination Vaccine Immune Response Manufacturing

Covid-19 vaccine success bolsters nanoparticle drug delivery research

Pharmaceutical Technology

APRIL 24, 2023

With early nanoparticle studies, researchers often found the human body’s innate immune response to drugs and the short-lasting effects of drugs challenging, as they can also reduce a drug’s efficacy. However, after a period of slow movement in the field, the FDA approved the first nanodrug, Doxil, for Kaposi sarcoma in 1995.

Drug Delivery

Drug Delivery Vaccination Vaccine Research

Sandoz’s Jubbonti and Wyost Approved as First Interchangeable Biosimilars to Amgen’s Bone Drugs Prolia and Xgeva

XTalks

MARCH 8, 2024

This means they can be substituted for the reference product at a pharmacy without the need for instruction from a prescriber. The biosimilar injections, Jubbonti (denosumab-bddz) and Wyost (denosumab-bddz), are approved as interchangeable biosimilars to Prolia and Xgeva, respectively.

Drugs

Drugs FDA Approval Production Immune Response

Regeneron Announces Encouraging Initial Data from COVID-19 Antibody Cocktail Trial in Hospitalized Patients on Low-flow Oxygen

The Pharma Data

DECEMBER 29, 2020

The analysis was prospectively designed to focus on patients who had not yet mounted their own immune response to SARS-CoV-2 (i.e., did not have antibodies at baseline: seronegative), as prior evidence suggested these patients were at greater risk. futility analysis). .

Antibody

Antibody Trials Production Clinical Trials

Regeneron’s Casirivimab and Imdevimab Antibody Cocktail for COVID-19 is First Combination Therapy to Receive FDA Emergency Use Authorization

The Pharma Data

NOVEMBER 20, 2020

The clinical evidence from Regeneron’s outpatient trial suggests that monoclonal antibodies such as casirivimab and imdevimab have the greatest benefit when given early after diagnosis and in patients who have not yet mounted their own immune response or who have high viral load.

Antibody

Antibody Production Clinical Trials Clinical Trials

Regeneron’s COVID-19 Outpatient Trial Prospectively Demonstrates that REGN-COV2 Antibody Cocktail Significantly Reduced Virus Levels and Need for Further Medical Attention

The Pharma Data

OCTOBER 28, 2020

“We continue to see the strongest effects in patients who are most at risk for poor outcomes due to high viral load, ineffective antibody immune response at baseline, or pre-existing risk factors. Yancopoulos , M.D., President and Chief Scientific Officer of Regeneron. Regeneron has shared these results with the U.S.

Antibody

Antibody Trials Production Clinical Trials

Regeneron’s REGEN-COV2 is First Antibody Cocktail for COVID-19 to Receive FDA Emergency Use Authorization

The Pharma Data

NOVEMBER 21, 2020

The clinical evidence from Regeneron’s outpatient trial suggests that monoclonal antibodies such as REGEN-COV2 have the greatest benefit when given early after diagnosis and in patients who have not yet mounted their own immune response or who have high viral load.

Antibody

Antibody Production Clinical Trials Clinical Trials

New England Journal of Medicine Publishes Positive Initial Regeneron Antibody Cocktail Results in Non-hospitalized Patients with COVID-19

The Pharma Data

DECEMBER 17, 2020

Senior Vice President and Head of Global Clinical Development at Regeneron and lead author of the publication. “The investigational cocktail is now available to indicated high-risk U.S. patients under an Emergency Use Authorization, and we also continue a robust clinical development program.”

Antibody

Antibody Medicine Production Trials

America Sees COVID Deaths Top 400,000, While New Variants Worry Scientists

The Pharma Data

JANUARY 20, 2021

“This is the first time I’ve been concerned about a variant partially evading the immune response and partially evading the vaccine.” ” Both experts stressed that people should still get the vaccine.

Scientist

Scientist Vaccination Vaccine Antibody

COVID-19 Pandemic Coverage

XTalks

SEPTEMBER 14, 2020

It was recently reported that the addition of an adjuvant to their vaccine led to enhanced immune responses that exceeded responses in convalescent serum from symptomatic COVID-19 patients. Novavax has also tested its recombinant SARS-CoV-2 nanoparticle adjuvanted vaccine in a Phase I/II trial.

Vaccination

Vaccination Vaccine Antibody Life Science

‘Warp Speed’ Officials Say U.S. COVID Vaccine Distribution Too Slow

The Pharma Data

DECEMBER 31, 2020

Right now, most shots are being given at hospitals, clinics and nursing homes, but Perna and Slaoui agreed that the pace of vaccination should pick up considerably once doses are given out by the major pharmacy chains. ” President-Elect Joe Biden has been critical of the slow pace of vaccine deployment.

Vaccination

Vaccination Vaccine Genetics Protein

Clinical Research Informer

Arexvy Shows Strong Efficacy Over Three RSV Seasons in New Phase III Data

FluMist Takes Flu Protection Home: FDA Approves Self-Administration

Webinars

Trending Sources

Shape Therapeutics-Roche’s Deal; AllStripes Raises $50M; Datavant-Real Chemistry’s Partnership; BlueWillow’s Nasal Vaccine

Webinars

20/20 Offering Lab Test for Measuring Antibody Levels Associated with Vaccine Efficacy

COVID-19 nasal vaccine candidate effective at preventing disease transmission

How the UAE’s COVID-19 Vaccination Strategy Differs from North America’s and Why It Matters

Covid-19 vaccine success bolsters nanoparticle drug delivery research

Sandoz’s Jubbonti and Wyost Approved as First Interchangeable Biosimilars to Amgen’s Bone Drugs Prolia and Xgeva

Regeneron Announces Encouraging Initial Data from COVID-19 Antibody Cocktail Trial in Hospitalized Patients on Low-flow Oxygen

Regeneron’s Casirivimab and Imdevimab Antibody Cocktail for COVID-19 is First Combination Therapy to Receive FDA Emergency Use Authorization

Regeneron’s COVID-19 Outpatient Trial Prospectively Demonstrates that REGN-COV2 Antibody Cocktail Significantly Reduced Virus Levels and Need for Further Medical Attention

Regeneron’s REGEN-COV2 is First Antibody Cocktail for COVID-19 to Receive FDA Emergency Use Authorization

New England Journal of Medicine Publishes Positive Initial Regeneron Antibody Cocktail Results in Non-hospitalized Patients with COVID-19

America Sees COVID Deaths Top 400,000, While New Variants Worry Scientists

COVID-19 Pandemic Coverage

‘Warp Speed’ Officials Say U.S. COVID Vaccine Distribution Too Slow

Stay Connected